MedTrace Logo

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

NCT07203391 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-04-23

No results posted yet for this study

Summary

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Conditions

  • Uveal Melanoma, Metastatic

Interventions

DRUG

roginolisib

Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)

Sponsors & Collaborators

  • St Vincent's Hospital, Sydney

    lead OTHER

Principal Investigators

  • Anthony Joshua, MBBS PhD FRACP · St Vinents Hospital sydney

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-12-01
Completion
2029-12-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07203391 on ClinicalTrials.gov